Journal article

Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses

Helen Tremlett, Ingrid Van der Mei, Fotini Pittas, Leigh Blizzard, Glenys Paley, Terence Dwyer, Bruce Taylor, Anne-Louise Ponsonby

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | JOHN WILEY & SONS LTD | Published : 2008

Abstract

BACKGROUND: Long-term immunomodulatory drug (IMD) treatment is now common in multiple sclerosis (MS). However, predictors of adherence are not well understood; past studies lacked lifestyle factors such as alcohol use and predictors of missed doses have not been evaluated. We examined both levels of non-adherence-stopping IMD and missing doses. METHODS: This longitudinal prospective study followed a population-based cohort (n = 199) of definite MS patients in Southern Tasmania (January 2002 to April 2005, source population 226 559) every 6 months. Baseline factors (demographic, clinical, psychological and cognitive) affecting adherence were examined by logistic regression and a longitudinal ..

View full abstract